'On standalone basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Pfizer has increased 9.13% to Rs 642.34 crore. Operating profit margin has jumped from 32.15% to 35.80%, leading to 21.50% rise in operating profit to Rs 229.93 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.32% to 9.92%. Purchase of finished goods cost rose from 15.07% to 31.36%. Employee cost decreased from 18.83% to 13.42%. Other expenses fell from 16.42% to 12.72%.
Other income fell 2.83% to Rs 41.85 crore. PBIDT rose 16.99% to Rs 271.78 crore. Provision for interest up 1.43% to Rs 2.13 crore. Loan funds rose to Rs 42.98 crore as of 30 September 2025 from Rs 36.94 crore as of 30 September 2024. Inventories rose to Rs 500.47 crore as of 30 September 202...
Pleaselogin & subscribe to view the full report.
More Reports
-
(15-Jan-2026)
Indian Overseas Bank
Strong loan growth, margins improve
-
(15-Jan-2026)
Infosys
Revenue up 9% YoY to Rs 45479 crore in Q3FY2026
-
(15-Jan-2026)
Tata Elxsi
Revenue up 1.5% yoy to Rs 953.5 crore in Q3FY2026
-
(15-Jan-2026)
Union Bank of India
Loan growth and margin improves
|
|